To evaluate the robustness of these observed effects, we performed similar experiments in melanoma, GIST, and lung cancer cell lines using AZD5991 or a BCL-2/BCL-XL inhibitor, AZD4320. This evidence concerns the gene BCL2 and gastrointestinal stromal tumor.